Pfizer (PFE) Aperçu de l'action
Pfizer Inc. découvre, développe, fabrique, commercialise, distribue et vend des produits biopharmaceutiques aux États-Unis et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
PFE Community Fair Values
Create NarrativeSee what 909 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativePfizer Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$26.30 |
| Plus haut sur 52 semaines | US$28.75 |
| Plus bas sur 52 semaines | US$21.97 |
| Bêta | 0.39 |
| Variation sur 1 mois | -7.13% |
| Variation sur 3 mois | 2.06% |
| Variation sur 1 an | 10.18% |
| Variation sur 3 ans | -31.99% |
| Variation sur 5 ans | -34.02% |
| Évolution depuis l'introduction en bourse | 5,704.15% |
Nouvelles et mises à jour récentes
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Pfizer: Why You Should Double Down Into Q1
May 01Recent updates
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Pfizer: Why You Should Double Down Into Q1
May 01
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Jan 08
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
Dec 18
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
Aug 12
Pfizer's Q1 Update May Mark A Bottom In The Stock
Apr 30Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Apr 23Pfizer: Tasty 7% Yield
Apr 16Rendement pour les actionnaires
| PFE | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | -1.8% | 4.4% | 0.6% |
| 1Y | 10.2% | 27.8% | 28.4% |
Rendement vs Industrie: PFE a sous-performé le secteur US Pharmaceuticals qui a rapporté 27.8 % au cours de l'année écoulée.
Rendement vs marché: PFE a sous-performé le marché US qui a rapporté 28.4 % au cours de l'année écoulée.
Volatilité des prix
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: PFE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PFE ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1849 | 75,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. découvre, développe, fabrique, commercialise, distribue et vend des produits biopharmaceutiques aux États-Unis et dans le monde entier. Elle opère dans trois secteurs : Biopharma, PC1 et Pfizer Ignite. L'entreprise propose des produits de médecine interne, notamment des produits contre les maladies cardiovasculaires et métaboliques sous la marque Eliquis ; des produits contre la migraine sous les marques Nurtec ODT/Vydura et Zavzpret ; des vaccins sous les marques Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, et Trumenba ; et Paxlovid pour le traitement du COVID-19.
Pfizer Inc. Résumé des fondamentaux
| PFE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$149.77b |
| Bénéfices(TTM) | US$7.75b |
| Recettes(TTM) | US$62.58b |
Le site PFE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PFE compte de résultat (TTM) | |
|---|---|
| Recettes | US$62.58b |
| Coût des recettes | US$15.14b |
| Marge brute | US$47.44b |
| Autres dépenses | US$39.69b |
| Les revenus | US$7.75b |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 05, 2026
| Résultat par action (EPS) | 1.36 |
| Marge brute | 75.81% |
| Marge bénéficiaire nette | 12.38% |
| Ratio dettes/capitaux propres | 74.9% |
Quelles ont été les performances à long terme de PFE?
Voir les performances historiques et les comparaisonsDividendes
Le site PFE verse-t-il des dividendes fiables ?
Voir PFE l'historique des dividendes et les indices de référence| Pfizer dates des dividendes | |
|---|---|
| Date ex-dividende | May 08 2026 |
| Date de paiement du dividende | Jun 12 2026 |
| Jours jusqu'au dividende Ex | 2 days |
| Jours jusqu'à la date de paiement du dividende | 37 days |
Le site PFE verse-t-il des dividendes fiables ?
Voir PFE l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/04 12:55 |
| Cours de l'action en fin de journée | 2026/05/04 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Pfizer Inc. est couverte par 44 analystes. 26 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |